Condition: Cytomegalovirus Infections · Sponsor: Centre Hospitalier Universitaire de Saint Etienne
CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus (QF-CMV) assay measures the immune response against CytoMegaloVirus (CMV) in a blood specimen.
This description comes directly from the study's public registry record.
Xavier ROBLIN, MD PhD · (0)477828119 · xavier.roblin@chu-st-etienne.fr
Sylvie PILLET, PhD · (0)477828315 · sylvie.pillet@chu-st-etienne.fr
Always discuss trial participation with your own doctor first.
| HCL-Hôpital Lyon Sud | Lyon, France | Recruiting |
| Chu Saint-Etienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04030676